Recurrent GlioblastomaPhase 2NCT01814813
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Phase 2 study testing HSPPC-96 and bevacizumab in people with Recurrent Glioblastoma and Recurrent Adult Brain Tumor, run by Alliance for Clinical Trials in Oncology at 417 sites in United States.
Trial summary
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- What is being tested?
- HSPPC-96 and bevacizumab
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 417 sitesUnited States
- Study dates
- 19 Jun 2013to 22 May 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Pre-registration (Pre-Surgery) Eligibility Criteria
- Histologic documentation: Prior histologic diagnosis of GBM at first occurrence
- Stage: First or second recurrence of GBM or gliosarcoma considered to be surgically resectable
- Prior Treatment:
- No radiotherapy within 90 days prior to pre-registration
- No prior treatment with any anti-angiogenic agent targeting the VEGF pathway including but not limited to bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept, or sorafenib
- No prior treatment with HSPPC-96 or other investigational immunotherapy
- Must have received prior treatment with radiotherapy and temozolomide for histologically confirmed GBM at initial diagnosis
- No tumor directed therapy for most recent progression
- No prior Gliadel® wafers
- No clinically significant cardiovascular disease:
- Patients with a history of hypertension must be well controlled (<150/90) on a regimen of antihypertensive therapy.
- History of arterial thrombotic events within the past 6 months, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medial intervention in the past 6 months, or myocardial infarction (MI). Patients with clinically significant peripheral artery disease (i.e., claudication on less than one block), significant vascular disease (i.e., aortic aneurysm, history of aortic dissection) are not eligible.
- Patients who have had a deep vein thrombosis or pulmonary embolus within the past 6 months are eligible if they are on stable therapeutic anticoagulation
- No current New York Heart Association classification II, III or IV congestive heart failure
- No significant bleeding within the past 6 months; no bleeding diathesis or coagulopathy
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within past 12 months
- No evidence of any systemic autoimmune disease (e.g. Hashimoto's thyroiditis) and/or any history of primary or secondary immunodeficiency, and no immunosuppressant therapy (with the exception of dexamethasone as noted below) for any reason
- Age ≥ 18 years of age
- Karnofsky functional status rating ≥70
- No more than 16 mg dexamethasone (or equivalent) per day
- Non-pregnant and non-nursing
Registration (Post-Surgery) Eligibility Criteria
- Pre-registration eligibility criteria continue to be met
- Histologic documentation: confirmed histological diagnosis of recurrent GBM or gliosarcoma
- ≥ 90% surgical resection of recurrent GBM confirmed by central radiology review by MRI with or without gadolinium per institutional guidelines. A CT scan is allowable in place of MRI only in situations where an MRI is contraindicated (e.g., patient has a heart pacemaker, metallic devices in the eye, brain or spine, severe claustrophobia).
- ≥ 7 grams of resected tumor available for vaccine manufacture as determined by institutional pathologist
- Availability of ≥ 6 clinical vials of HSPPC-96
- Required Initial Laboratory Values:
- Granulocytes ≥1,500/µL
- Platelet count ≥100,000/µL
- Total Bilirubin ≤ 2.0 x ULN
- UPC ratio <1 or Urine protein ≤ 1+
- Calculated creatinine clearance ≥ 45 ml/min
- SGOT/SGPT(AST/ALT) ≤ 2.5 x ULN
- No serious, non-healing wounds or ulcers
- At least 7 days since any minor surgery such as port placement
- No major surgical procedures, open biopsy or significant traumatic injury ≤ 28 days prior to registration or anticipation of need for elective or planned major surgical procedure during the study. Core biopsy or other minor surgical procedures ≤7 days prior to registration.
- No active or recent hemoptysis (≥½ teaspoon of bright red blood per episode) ≤ 30 days prior to registration
- No new bleeding on D28 (+/-3) MRI (or CT if MRI is contraindicated)
- No clinical deterioration at the time of registration/randomization
- If a second surgery is needed for completion of resection, this should be within 30 days from the first surgery
Trial locations and contacts
417 sites in 1 country.
300 sites in 1 country
United States300 sites
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Bixby Medical Center
Adrian, Michigan, 49221
Hickman Cancer Center
Adrian, Michigan, 49221
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Community Hospital of Anaconda
Anaconda, Montana, 59711
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Anchorage Radiation Therapy Center
Anchorage, Alaska, 99504
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Alaska Regional Hospital
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Piedmont Hospital
Atlanta, Georgia, 30309
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Swedish Cancer Institute-Eastside Oncology Hematology
Bellevue, Washington, 98005
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Saint Charles Health System
Bend, Oregon, 97701
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Frontier Cancer Center and Blood Institute-Billings
Billings, Montana, 59102
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Tufts Medical Center
Boston, Massachusetts, 02111
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Toledo Clinic Cancer Centers-Bowling Green
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Saint Vincent's Medical Center
Bridgeport, Connecticut, 06606
Saint Joseph Regional Cancer Center
Bryan, Texas, 77802
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Highline Medical Center-Main Campus
Burien, Washington, 98166
Mills - Peninsula Hospitals
Burlingame, California, 94010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Eden Hospital Medical Center
Castro Valley, California, 94546
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Memorial Hospital
Chattanooga, Tennessee, 37404
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Northwestern University
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, 45219
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Oncology and Hematology Care Southeast
Clackamas, Oregon, 97015
Case Western Reserve University
Cleveland, Ohio, 44106
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Greater Regional Medical Center
Creston, Iowa, 50801
Sutter Davis Hospital
Davis, California, 95616
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Health Center
Dayton, Ohio, 45415
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Porter Adventist Hospital
Denver, Colorado, 80210
Colorado Blood Cancer Institute
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Epic Care-Dublin
Dublin, California, 94568
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Essentia Health Saint Mary's Medical Center
Duluth, Minnesota, 55805
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Duke University Medical Center
Durham, North Carolina, 27710
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Swedish Medical Center-Edmonds
Edmonds, Washington, 98026
Crossroads Cancer Center
Effingham, Illinois, 62401
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Saint Elizabeth Hospital
Enumclaw, Washington, 98022
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Providence Regional Cancer Partnership
Everett, Washington, 98201
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Saint Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Hospital
Findlay, Ohio, 45840
Hurley Medical Center
Flint, Michigan, 48502
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Radiation Oncology Associates PC
Fort Wayne, Indiana, 46804
Parkview Hospital Randallia
Fort Wayne, Indiana, 46805
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology Inc
Fredericksburg, Virginia, 22401
Kaiser Permanente-Fremont
Fremont, California, 94538
Fresno Cancer Center
Fresno, California, 93720
Kaiser Permanente
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Altru Cancer Center
Grand Forks, North Dakota, 58201
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
East Carolina University
Greenville, North Carolina, 27858
Wayne Hospital
Greenville, Ohio, 45331
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Saint Peter's Community Hospital
Helena, Montana, 59601
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, 37343
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas, 71913
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Franciscan Health Indianapolis
Indianapolis, Indiana, 46237
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
Allegiance Health
Jackson, Michigan, 49201
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
Heartland Hematology and Oncology
Kearney, Nebraska, 68845
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Community Howard Regional Health
Kokomo, Indiana, 46904
IU Health La Porte Hospital
La Porte, Indiana, 46350
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Saint Clare Hospital
Lakewood, Washington, 98499
Sparrow Hospital
Lansing, Michigan, 48912
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Kansas Institute of Medicine Cancer and Blood Center
Lenexa, Kansas, 66219
Minimally Invasive Surgery Hospital
Lenexa, Kansas, 66219
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Lima Memorial Hospital
Lima, Ohio, 45804
Nebraska Cancer Research Center
Lincoln, Nebraska, 68510
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Littleton Adventist Hospital
Littleton, Colorado, 80122
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Jewish Hospital
Louisville, Kentucky, 40202
Norton Hospital Pavilion and Medical Campus
Louisville, Kentucky, 40202
Saints Mary and Elizabeth Hospital
Louisville, Kentucky, 40215
Jewish Hospital Medical Center Northeast
Louisville, Kentucky, 40245
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Fairview Maple Grove Medical Center
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marquette General Hematology Oncology
Marquette, Michigan, 49855
Marquette General Hospital
Marquette, Michigan, 49855
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Maumee, Ohio, 43537
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46544
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Montana Cancer Specialists
Missoula, Montana, 59802
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Community Medical Hospital
Missoula, Montana, 59804
Memorial Medical Center
Modesto, California, 95355
Kaiser Permanente-Modesto
Modesto, California, 95356
Mercy Memorial Hospital
Monroe, Michigan, 48162
Toledo Clinic Cancer Centers-Monroe
Monroe, Michigan, 48162
Palo Alto Medical Foundation-Camino Division
Mountain View, California, 94040
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, 94040
Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho, 83686
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08903
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Columbia University/Herbert Irving Cancer Center
New York, New York, 10032
Providence Newberg Medical Center
Newberg, Oregon, 97132
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Tumor Institute
Oakland, California, 94609
Kaiser Permanente Oakland-Broadway
Oakland, California, 94611
Kaiser Permanente-Oakland
Oakland, California, 94611
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Hemotology and Oncology Consultants PC
Omaha, Nebraska, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Memorial GYN Plus
Ooltewah, Tennessee, 37363
Saint Charles Hospital
Oregon, Ohio, 43616
Toledo Clinic Cancer Centers-Oregon
Oregon, Ohio, 43616
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Palo Alto Medical Foundation Health Care
Palo Alto, California, 94301
Stanford Cancer Institute
Palo Alto, California, 94304
Midlands Community Hospital
Papillion, Nebraska, 68046
The Valley Hospital-Luckow Pavilion
Paramus, New Jersey, 07652
Parker Adventist Hospital
Parker, Colorado, 80138
Rocky Mountain Cancer Centers-Parker
Parker, Colorado, 80138
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Memorial Hospital West
Pembroke Pines, Florida, 33028
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon, 97210
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Kootenai Cancer Center
Post Falls, Idaho, 83854
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, 98370
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
About this study
Official title: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them. It is not yet known whether giving vaccine therapy is more effective with or without bevacizumab in treating glioblastoma multiforme.
Read the detailed description
The purpose of this study is to compare the effects of a vaccine with bevacizumab versus bevacizumab alone on a patient's brain tumor. The vaccine is called heat shock protein peptide complex 96 (HSPPC-96). HSPPC-96 is experimental. Specifically, HSPPC-96 is a protein that may work to help the body have a response against remaining brain tumor cells. Bevacizumab has been approved by the Food and Drug administration for treating brain tumors that grow back. In this study, patients will either get HSPPC-96 vaccine at the same time as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or bevacizumab alone. The use of HSPPC-96 and bevacizumab is investigational.
The primary objective of the study is to determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent glioblastoma multiforme.
The secondary objectives are:
- to evaluate the safety and tolerability of HSPPC-96 with bevacizumab
- to evaluate the progression free survival of HSPPC-96 with bevacizumab, given concomitantly or at the point of progression.
Patients must undergo surgery within 28 days from pre-registration. There must be confirmation of adequacy of tissue for vaccine manufacture, tumor tissue submitted to Agenus, confirmation of ≥ 90% resection by central radiology review and vaccine manufacture of at least six vials. Patients will be randomized to one of three treatment arms. Please see the "Arms" section for more details.
Patients will be monitored approximately 5 years post-surgery.
- Being tested
- HSPPC-96, bevacizumab
- Medical subject headings
- Glioblastoma, Brain Neoplasms, Gliosarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HSPPC-96Biological
intradermal infusion
bevacizumabDrug
intravenous
| Study group | Role | What they receive |
|---|---|---|
| Arm 1, HSPPC-96 + concomitant bevacizumab | Experimental | HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)
Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression. Receives: Biological: HSPPC-96; Drug: bevacizumab |
| Arm 2, HSPPC-96 with bevacizumab at progression | Experimental | HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)
NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.
Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine. Receives: Biological: HSPPC-96; Drug: bevacizumab |
| Arm 3, Bevacizumab | Active comparator | Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days) Receives: Drug: bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
The primary endpoint is overall survival (OS), which is defined as the date from study> registration to the date of death, due to any cause.
Measured: Up to 5 years post-surgery
Secondary outcomes (2)
Progression Free Survival (PFS)
Time to progression free survival: which is defined as the date from study registration to the date of first observation of disease progression or death due to any cause (whichever comes first). Progressive disease is defined as one or more of the following:New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids, increase by > 50% enhancement from the first post-surgical scan, or a subsequent scan with smaller tumor size, and the scan 8 weeks or later on stable or increasing doses of corticosteroids, clinical deterioration not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment, for patients receiving bevacizumab therapy, significant increase in T2/FLAIR non-enhancing lesion.
Measured: Up to 5 years post-surgery
Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5)
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2013 (estimated)
- Study start19 Jun 2013
- Primary completion3 Apr 2017
- Study completion22 May 2023
Why it stopped: DSMB futility analysis
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Recurrent GlioblastomaStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Agenus Inc.
- Responsible party
- Sponsor
- Investigators
- Ian Parney, MD, PhD, Study chair, Mayo ClinicOrin Bloch, MD, Study chair, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01814813
- Sponsor's protocol ID
- A071101
- Other IDs
- U10CA031946, NCI-2013-00444
- Status last verified
- Jan 2025
- First submitted
- 18 Mar 2013
- Last updated
- 24 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- ClinicalTrials.gov ID
- NCT01814813
- Acronym / sponsor ID
- A071101
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: DSMB futility analysis
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Agenus Inc.
- Study start
- 19 Jun 2013 (actual)
- Primary completion
- 3 Apr 2017 (actual)
- Study completion
- 22 May 2023 (actual)
- First posted
- 20 Mar 2013 (estimated)
- Results
- Posted 12 Jun 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them. It is not yet known whether giving vaccine therapy is more effective with or without bevacizumab in treating glioblastoma multiforme.
Detailed description
The purpose of this study is to compare the effects of a vaccine with bevacizumab versus bevacizumab alone on a patient's brain tumor. The vaccine is called heat shock protein peptide complex 96 (HSPPC-96). HSPPC-96 is experimental. Specifically, HSPPC-96 is a protein that may work to help the body have a response against remaining brain tumor cells. Bevacizumab has been approved by the Food and Drug administration for treating brain tumors that grow back. In this study, patients will either get HSPPC-96 vaccine at the same time as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or bevacizumab alone. The use of HSPPC-96 and bevacizumab is investigational.
The primary objective of the study is to determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent glioblastoma multiforme.
The secondary objectives are:
- to evaluate the safety and tolerability of HSPPC-96 with bevacizumab
- to evaluate the progression free survival of HSPPC-96 with bevacizumab, given concomitantly or at the point of progression.
Patients must undergo surgery within 28 days from pre-registration. There must be confirmation of adequacy of tissue for vaccine manufacture, tumor tissue submitted to Agenus, confirmation of ≥ 90% resection by central radiology review and vaccine manufacture of at least six vials. Patients will be randomized to one of three treatment arms. Please see the "Arms" section for more details.
Patients will be monitored approximately 5 years post-surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1, HSPPC-96 + concomitant bevacizumab | Experimental | Biological: HSPPC-96, Drug: bevacizumabHSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days) Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression. |
| Arm 2, HSPPC-96 with bevacizumab at progression | Experimental | Biological: HSPPC-96, Drug: bevacizumabHSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days) NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab. Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine. |
| Arm 3, Bevacizumab | Active comparator | Drug: bevacizumabBevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HSPPC-96intradermal infusion | Biological | Arm 1, HSPPC-96 + concomitant bevacizumab, Arm 2, HSPPC-96 with bevacizumab at progression |
| bevacizumabintravenous | Drug | Arm 1, HSPPC-96 + concomitant bevacizumab, Arm 2, HSPPC-96 with bevacizumab at progression, Arm 3, Bevacizumab |
Primary outcome
Overall Survival (OS)
Time frame: Up to 5 years post-surgery
The primary endpoint is overall survival (OS), which is defined as the date from study> registration to the date of death, due to any cause.
2 secondary outcomes
Progression Free Survival (PFS)
Time frame: Up to 5 years post-surgery
Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5)
Time frame: Up to 3 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Recurrent Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
RecruitingObservational study
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
Glioblastoma Multiforme
Active, not recruitingPhase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Glioblastoma, Recurrent Glioblastoma
RecruitingPhase 1
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Glioblastoma Multiforme of Brain, Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ian Parney, MD, PhD study chair
Mayo Clinic
Orin Bloch, MD study chair
Northwestern University
417 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing HSPPC-96 and bevacizumab in people with Recurrent Glioblastoma and Recurrent Adult Brain Tumor, run by Alliance for Clinical Trials in Oncology at 417 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 417 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Jun 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: Up to 5 years post-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2025.